News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Collaboration is not an unknown in the domain of pharmaceutical development, but it is rare enough. The demands of the COVID-19 pandemic, however, have seen competitors switch to become manufacturing allies.
In recent months we have seen companies investing in capacity and technology around pre-fillable systems for both new injectable drugs and vaccines.
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday.
Biofoundries and a distributed manufacturing model are the fix the troubled vaccine industry needs, say the authors of a new review.
BioNTech announced this morning it has started the production of mRNA at its new facility in Marburg, Germany: which will become one of the largest mRNA manufacturing sites in Europe.